J Refract Surg. 2021 Jun;37(S1):S28-S34. doi: 10.3928/1081597X-20210408-06. Epub 2021 Jun 1.
Presbyopia affects 1.8 billion people worldwide. This reduction in distance corrected near visual acuity impacts quality of life, which prompts patients to seek treatment. Presbyopia is an early manifestation of the "crystalline lens optical dysfunction through aging," or dysfunctional lens syndrome, and appropriate management of presbyopia is dependent on coexisting factors such as increased higher order aberrations, reduced contrast sensitivity, light scatter, and lenticular opacification. This review of published literature (PubMed and MEDLINE) is presented in narrative format and discusses medical and surgical treatments available to patients who experience presbyopia, while highlighting future therapies. Numerous strategies exist for the management of presbyopia. These strategies include pharmacological therapy, glasses and contact lenses, corneal, scleral, and lenticular procedures. This article discusses the role of several new and existing presbyopia treatments, as well as which patients are candidates for these novel therapies. Although no single treatment is ideal for all patients with presbyopia, new medical and surgical strategies increase the number of options available when addressing different stages of presbyopia and dysfunctional lens syndrome. .
全球有 18 亿人受老花眼影响。这种矫正近距离视觉的能力下降会影响生活质量,促使患者寻求治疗。老花眼是“晶状体光学功能随年龄下降”或“晶状体功能障碍综合征”的早期表现,老花眼的适当治疗取决于共存的因素,如高阶像差增加、对比敏感度降低、光散射和晶状体混浊。本综述对已发表的文献(PubMed 和 MEDLINE)进行了叙述性分析,讨论了患有老花眼的患者可选择的医疗和手术治疗方法,同时强调了未来的治疗方法。有许多策略可用于老花眼的管理。这些策略包括药物治疗、眼镜和隐形眼镜、角膜、巩膜和晶状体手术。本文讨论了几种新的和现有的老花眼治疗方法的作用,以及哪些患者是这些新型治疗方法的候选者。虽然没有单一的治疗方法对所有老花眼患者都理想,但新的医疗和手术策略增加了在处理不同阶段的老花眼和晶状体功能障碍综合征时的选择。